Mankind Pharma Approves Wholly Owned Subsidiary Amalgamation and Reports Q2 Financials
Mankind Pharma Ltd · Others (Uncategorized) · 26 Oct 2026, 8:54 pm
Mankind Pharma Approves Wholly Owned Subsidiary Amalgamation and Reports Q2 Financials Mankind Pharma approved the amalgamation of wholly owned subsidiaries Prolijune Lifesciences and Pavi Buildwell into the parent entity, with an appointed date of 1st Apr'27, involving no share issuance or cash consideration. For Q2 ended 30th Sep'26, consolidated revenue from operations grew 17.3% YoY to ₹4,337.86 crore, while consolidated profit after tax rose 37.7% YoY to ₹716.12 crore. Separately, the board noted the merger of step-down subsidiary Upakarma Ayurveda into Mankind Consumer Products to optimize operations and strengthen direct-to-consumer capabilities.
Original exchange filing (PDF)
More announcements from Mankind Pharma Ltd
- Please find attached intimation regarding change in Corporate Office Address of RTA · 13 Nov 2026
- Please find attached Intimation of participation in the Investor Conference · 06 Nov 2026
- Please find attached intimation regarding ESG Rating · 05 Nov 2026
- Intimation of participation in the Investor Conference. · 03 Nov 2026
- Please find attached transcript of the Earnings Conference Call for Q2 & H1 FY27 · 30 Oct 2026
- Please find attached intimation regarding re-affirmation/withdrawl of Credit Rating by CRISIL · 30 Oct 2026
- In continuation of our earlier intimation dated October 22, 2026 please find attached the Investor Presentation to be made during the said Analyst / Institutional Investors meet · 27 Oct 2026
- Please find attached link for audio recording of the Investor Conference Call held on October 26, 2026 · 27 Oct 2026
